Advertorial: EMA REAFFIRMS POSITIVE BENEFIT-RISK BALANCE OF BAYER’S XARELTO® FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION

Authors

  • Bayer Advertorial

DOI:

https://doi.org/10.24170/13-1-1694

Abstract

Xarelto® for stroke prevention in patients with atrial fibrillation.

Downloads

Download data is not yet available.

Downloads

Published

2017-03-20

How to Cite

Advertorial, B. (2017). Advertorial: EMA REAFFIRMS POSITIVE BENEFIT-RISK BALANCE OF BAYER’S XARELTO® FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION. SA Heart Journal, 13(1), 42–43. https://doi.org/10.24170/13-1-1694

Issue

Vol. 13 No. 1 (2016): Summer

Section

News

License

This journal is an open access journal, and the authors and journal should be properly acknowledged, when works are cited.

Authors may use the publishers version for teaching purposes, in books, theses, dissertations, conferences and conference papers. 

A copy of the authors’ publishers version may also be hosted on the following websites:

  • Non-commercial personal homepage or blog.
  • Institutional webpage.
  • Authors Institutional Repository.

The following notice should accompany such a posting on the website: “This is an electronic version of an article published in SAHJ, Volume XXX, number XXX, pages XXX–XXX”, DOI. Authors should also supply a hyperlink to the original paper or indicate where the original paper (http://www.journals.ac.za/index.php/SAHJ) may be found.

Authors publishers version, affiliated with the Stellenbosch University will be automatically deposited in the University’s’ Institutional Repository SUNScholar.

Articles as a whole, may not be re-published with another journal.

Copyright Holder: SA Heart Journal

The following license applies:

Attribution CC BY-NC-ND 4.0

Most read articles by the same author(s)